Daiichi Sankyo Streamlines Corporate, R&D Organizations
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As part of the process of giving the finishing touches on the merger of the former Daiichi and Sankyo pharmaceutical companies, Daiichi Sankyo, the second-largest Japanese pharmaceutical firm, will revamp its corporate and research and development divisions, effective April 1, the company announced Feb. 22. The reorganization in part is aimed at boosting its global presence by proactively mobilizing Indian subsidiary Ranbaxy resources, a company spokesman explained Feb. 23
You may also be interested in...
Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
Analysts See Japan’s Biggest Drug Industry Loss By Daiichi Sankyo
Daiichi Sankyo is expected to report the biggest annual loss of any Japanese drug maker, with a 2008 deficit of $3.2 billion. Six analysts surveyed for their estimates provided a median estimate for the amount of loss. The steep drop was caused primarily by write-downs Daiichi Sankyo had to take for its takeover of Ranbaxy Laboratories. A Daiichi Sankyo spokeswoman declined to comment ahead of a scheduled release of the firm's earnings report. The company forecast in October a net income for the year, before it announced the write-downs. (Click here for more